Addition Technology Expands International Intacs® SK Product Line

Jan. 9, 2009 - PRLog -- As a result of the expansion, refractive surgeons can now treat more severe stages of keratoconus through this minimally invasive sight-restoring procedure. “Since the introduction of Intacs SK in January 2007, I have been able to treat a broader number of keratoconus cases in my practice.  As a result of its unique elliptical design and diameter, we have experienced no complaints of halo and glare as with other implants and I now have many satisfied patients.” states Mark Swanson, M.D. of Agua Prieta, Mexico.  
Intacs and Intacs SK reshape the cornea with the goal of helping patients achieve functional vision and avoid a transplant. Patients failing to achieve a successful contact lens fit have historically been faced with a corneal transplant with a 12 to 18 month recovery period. Intacs and Intacs SK are far less risky options to provide keratoconus patients with functional vision. An important benefit of the Intacs technology is that the product can be exchanged or removed, maintaining corneal integrity and providing the surgeon with further surgical options if necessary.  “This product is a world-class performer stabilizing many unstable corneas.  Medically, Intacs is the best first option before considering a more invasive corneal transplant for my contact lens intolerant patients,” says Luis Rodriguez, M.D. of Trinidad, Venezuela.
   Addition Technology, Inc., a privately held eye care company, specializes in novel solutions for sight-threatening eye indications. Intacs® corneal implants and the AlphaCor™ artificial cornea are patented devices, and the first of their kind, approved by the FDA and granted CE Mark certification in Europe in addressing vision threatening conditions of the cornea. Intacs® corneal implants are indicated for keratoconus and myopia. AlphaCor™ artificial cornea is indicated as an alternative for high-risk, repeat graft failures.

# # #

Addition Technology, Inc. is a privately held eye care company, specializing in novel solutions for sight-threatening eye indications.